ECE2016 Eposter Presentations Pituitary - Clinical (83 abstracts)
Introduction: Acromegaly is characterized by excessive secretion of GH and increased IGF-1 levels caused by benign pituitary adenoma. The ACRO-POLIS study describes symptoms and comorbidities of acromegaly at diagnosis in a large cohort of patients diagnosed between 2009 and 2014 in France.
Methodology: Observational, cross-sectional, multicentre study included adult patients with acromegaly diagnosed for less than 5 years. Data were collected retrospectively from patient medical files and from patientsquestionnaires.
Results: 472 patients were included. Mean (±S.D.) age was 51.9 (±14.3) years and 57.2% were female. GH- and GH/PRL-secreting pituitary adenomas were reported in 78.8% and 18.2% of patients, respectively. Most patients had a macroadenoma (80.5%). At diagnosis, mean (±S.D.) GH level and IGF-1 level were 18.7 (±30.1) ng/L and 295 (±160) %ULN respectively. Mean time between symptom or comorbidity onset and diagnosis of acromegaly was 5.1 (±6.75) years. The symptoms are mainly morphological manifestations, snoring and weight gain and were detected earlier in females than in males [enlargement of hands: 7.4 (±7.4) years vs. 5.6 (±6.3) years; enlargement of feet: 6.7 (±6.7) years vs. 5.8 (±7.0) years; snoring: 9.1 (±8.5) years vs. 5.9 (±6.7) years; weight gain: 6.6 (±5.9) years vs. 4.9 (±5.7) years]. Majority of signs were predominantly reported in the patients questionnaires and less in the patients medical records. The rates of important symptoms reported only in questionnaires are: snoring (40.4%), weight gain (50.2%), loss of libido (74.4%), rachialgia (61.7%), asthenia (35.8%), arthropathy (30.4%).
Conclusion: In ACRO-POLIS study, symptoms and comorbidities associated with acromegaly were different in terms of time to diagnosis between males and females. Furthermore, the study highlights the value of collecting data directly from the patients questionnaire in complement with the patients medical record.